Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $5.3 million.

  • Amicus Therapeutics' Other Non-Current Liabilities fell 6068.86% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 6068.86%. This contributed to the annual value of $7.1 million for FY2024, which is 4656.68% down from last year.
  • As of Q3 2025, Amicus Therapeutics' Other Non-Current Liabilities stood at $5.3 million, which was down 6068.86% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Other Non-Current Liabilities registered a high of $27.3 million during Q2 2021, and its lowest value of $5.3 million during Q3 2025.
  • For the 5-year period, Amicus Therapeutics' Other Non-Current Liabilities averaged around $15.5 million, with its median value being $13.3 million (2023).
  • As far as peak fluctuations go, Amicus Therapeutics' Other Non-Current Liabilities skyrocketed by 5037.94% in 2024, and later plummeted by 6068.86% in 2025.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Other Non-Current Liabilities stood at $20.3 million in 2021, then increased by 5.3% to $21.4 million in 2022, then plummeted by 37.98% to $13.3 million in 2023, then crashed by 46.57% to $7.1 million in 2024, then fell by 25.35% to $5.3 million in 2025.
  • Its Other Non-Current Liabilities stands at $5.3 million for Q3 2025, versus $8.6 million for Q2 2025 and $8.5 million for Q1 2025.